Casdin Capital — 2021 Investments
7 investments dated 2021 · listed companies and verified rows first · show all
Absci uses an AI-based drug creation platform combined with wet lab validation to design biologic therapeutics such as antibodies from scratch.
AI & Machine LearningBiotechDeep TechPortland, US
Sean McClain(Executive Officer)inPhil Barish(Executive Officer)
BoardZach Jonasson(Director)Daniel Gold(Director)Bryan Lawlis(Director)
Board seatEli Casdin· per SEC Form D · $125M raise · filed Mar 2021
Co-investorsDas & Co.Oregon Venture FundPhoenix Venture PartnersTachyon VenturesTau VenturesBiotechnology Value Fund+2 more
Century Therapeutics develops allogeneic, iPSC-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer.
BiotechHealthtechMedical DevicesPhiladelphia, US
Board seatEli Casdin· per SEC Form D · $160M raise · filed Mar 2021
Co-investorsVersant Ventures
C2i Genomics develops TrueMRD, a cancer monitoring platform that combines whole-genome sequencing with AI algorithms to build personalized tumor signatures for detecting minimal residual disease (MRD).
AI & Machine LearningBiotechHealthtechNew York, US
Asaf Zviran(Founder)inEzra Sofer(Executive Officer, Director)
BoardAlex Parker(Director)Shaun Rodriguez(Director)in
Board seatEli Casdin· per SEC Form D
Co-investorsiGlobe PartnersLionBirdNFXSection 32
BiotechCambridge, US
Alexandra Glucksmann(Executive Officer, Director)Dominik Naczynski(Director)Chris Bowden(Director)Jake Simson(Director)Rosana Kapeller(Director)
BoardAbbie Celniker(Director)in
Board seatEli Casdin· per SEC Form D · $82.6M raise · filed Oct 2021
Co-investorsThird Rock Ventures
Genomatica (Geno) develops biotechnology processes to produce bio-based chemicals and materials—such as 1,4-butanediol (BDO), butylene glycol for cosmetics, and plant-based nylon—as alternatives to fossil-fuel-derived inputs.
BiotechCircular EconomyCleantechClimate TechNew MaterialsSan Diego, US
Christophe Schilling(Co-founder (former CEO))Bernhard Palsson(Co-founder)Thomas McDonald(Executive Officer)Carlos A. Cabrera(Executive Chairman)John G. Gugel(Chief Executive Officer)Tom McDonald(SVP, Finance & Chief Financial Officer)
Board seatEli Casdin· per SEC Form D · $119.1M raise · filed Aug 2021
Co-investorsVantagePoint Capital PartnersNovo Holdings
SomaLogic develops proteomics tools that help researchers measure protein function and study human biology across a range of scientific applications.
BiotechDeep TechHealthtechBoulder, US
Larry Gold(Director)Larry Gold PhD(Founder)inDaniel Muehl(Executive Officer)Byron Hewett(Executive Officer, Director)
BoardCharles Lillis(Director)Youichi Yabuuchi(Director)
Board seatEli Casdin· per SEC Form D · $250M raise · filed Jan 2021
Co-investorsForesite CapitalKhosla Ventures
Boston, US
Jacob A. Donoghue, M.D., Ph.D.(Executive Officer, Director)Jarrett Revels(Executive Officer)Jacob A. Donoghue(Executive Officer, Director, Promoter)
BoardCaitlin Donovan(Director)Pavel Raifeld(Director)Naveen Rao(Director)
Co-investorsCatalio Capital Management, LPGeneral CatalystGV (Google Ventures)Iaso VenturesKicker VenturesIndicator Ventures+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.